Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | monarcHER: final OS results of abemaciclib in HR+, HER+ breast cancer

Fabrice André, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses data from the Phase II monarcHER trial (NCT02675231) of abemaciclib, a selective CDK4/6 inhibitor, in patients with HR-positive, HER2-positive advanced breast cancer. Patients were either randomized to receive trastuzumab with chemotherapy, abemaciclib with trastuzumab, or abemaciclib and trastuzumab with fulvestrant. Patients receiving the triple therapy were reported to have superior overall survival (OS) results. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.